Ronald W. Barrett, Ph.D.
Chief Executive Officer and Director
Ronald W. Barrett is one of our founders and has served as our chief executive officer since 2001. He served as our chief scientific officer from 1999 to 2001. Dr. Barrett has been a director since August 1999. From 1989 to 1999, he held various positions at Affymax Research Institute, the most recent of which was senior vice president of research (acquired by Glaxo Welcome plc, now known as GSK, in 1995). Prior to Affymax Research Institute, Dr. Barrett was a molecular pharmacologist in the Neuroscience Group at Abbott Laboratories from 1986 to 1989. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from Rutgers University.
Paul L. Berns
Director
Paul L. Berns has been a member of our board of directors since November 2005. He has served as a self-employed consultant to the pharmaceutical industry since September 2012. From March 2006 to August 2012, he served as president and chief executive officer, and a member of the board of directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in August 2012. From 2002 to 2005, Mr. Berns was chief executive officer, president and a director of Bone Care International, Inc. (acquired by Genzyme Corporation in 2005). From 2001 to 2002, Mr. Berns served as vice president and general manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. He served as vice president, marketing of BASF Pharmaceuticals-Knoll from 2000 to 2001. From 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns received a B.S. from the University of Wisconsin. Mr. Berns is also a member of the boards of directors of Anacor Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc.
Dennis M. Fenton, Ph.D.
Director
Dennis M. Fenton has been a member of our board of directors since August 2009. From 1982 to 2008, Dr. Fenton held numerous positions including executive roles in process development, manufacturing, sales and marketing and research and development at Amgen, Inc. From 2000 to 2008, he was executive vice president responsible for worldwide operations, manufacturing, process development and quality. From 1995 to 2000, he was senior vice president of operations, and from 1992 to 1995, he was senior vice president of sales, marketing and process development for Amgen. Dr. Fenton received a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University. He is currently a member of the board of directors for Hospira, Inc.
John G. Freund, M.D.
Director
John G. Freund has been a member of our board of directors since 1999 and our lead independent director since July 2008. He has served as a managing director of Skyline Ventures, a venture capital firm specializing in healthcare companies since 1997. From 1995 to 1997, Dr. Freund was a managing director in the private equity group at Chancellor Capital Management. AMVESCAP plc acquired Chancellor Capital Management in 1998 and renamed the division INVESCO Private Capital. In 1995, he co-founded Intuitive Surgical, Inc. From 1988 to 1994, he held various positions at Acuson Corp. most recently as executive vice president. Siemens Corp. acquired Acuson in 2000. Prior to Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co. where he was a co-founder of the Healthcare Group in the Corporate Finance Department. He received a B.A. from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School. Dr. Freund is a member of the boards of directors of SMALLCAP World Fund, Fundamental Investors, Inc. and The Growth Fund of America, Inc., which are U.S.-registered investment funds, and MAKO Surgical Corp.
Catherine J. Friedman
Director
Catherine J. Friedman has been a member of our board of directors since September 2007. She has served as an independent financial consultant to private and public companies in the life sciences industry since 2006. Prior to that, Ms. Friedman held numerous positions over a 23-year investment banking career with Morgan Stanley & Co., including Managing Director from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice from 1993 to 2006. Ms. Friedman received a B.A. from Harvard College and an M.B.A. from the University of Virginia Darden School of Business. Ms. Friedman is a member of the board of directors of EnteroMedics Inc.
Jeryl L. Hilleman
Director
Jeryl L. Hilleman has been a member of our board of directors since January 2005. She was the chief financial officer of Amyris Biotechnologies, Inc. from January 2008 to May 2012. Prior to joining Amyris in January 2008, she was executive vice president and chief financial officer of Symyx Technologies, Inc. from 1997 to June 2007. Prior to joining Symyx, Ms. Hilleman served as vice president finance and chief financial officer of two public biotechnology companies, Geron Corporation and Cytel Corporation, which merged with Epimmune Inc. in 1999. Ms. Hilleman received an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.
Ernest Mario, Ph.D.
Director
Ernest Mario, Ph.D., has been a member of our board since June 2012. He has served as chairman of the board and chief executive officer of Capnia, Inc. since 2007. From April 2003 to August 2007, Dr. Mario served as chairman of the board and chief executive officer of Reliant Pharmaceuticals, Inc. Prior to joining Reliant Pharmaceuticals, Dr. Mario was chairman and chief executive officer of ALZA Corporation from 1997 to 2001 and was co-chairman and chief executive officer of ALZA from 1993 to 1997. Prior to joining ALZA, Dr. Mario served as chief executive of Glaxo Holdings plc, a pharmaceutical company, from 1989 to 1993, and as deputy chairman from 1992 to 1993. Dr. Mario received a Ph.D. and an M.S. in physical sciences from the University of Rhode Island and a B.S. in pharmacy from the Ernest Mario School of Pharmacy at Rutgers University. He is chairman of the American Foundation for Pharmaceutical Education. In 2007, he was awarded the Remington Medal by the American Pharmacists Association, pharmacy’s highest honor. He is currently a member of the boards of directors for Boston Scientific Corporation, Celgene Corporation, Maxygen, Inc. and Vivus, Inc.
William J. Rieflin
Director
William J. Rieflin has been a member of our board of directors since September 2010. He has served as chief executive officer and a member of the board of directors of NGM Biopharmaceuticals, Inc.since 2010. He was previously president of XenoPort, Inc. from 2004 to September 2010. From 1996 to 2004, he held various positions with Tularik Inc., the most recent of which was executive vice president, administration, chief financial officer, general counsel and secretary. Amgen Inc. acquired Tularik in 2004. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School. Mr. Rieflin is a member of the board of directors of Anacor Pharmaceuticals, Inc.
Wendell Wierenga, Ph.D.
Director
Wendell Wierenga has been a member of our board of directors since 2000. He has served as executive vice president, research and development at Santarus, Inc. since 2011. He was previously executive vice president of research and development at Ambit Biosciences, Inc. since January 2007. Dr. Wierenga served as executive vice president of research and development at Neurocrine Biosciences, Inc. from 2003 to 2007. From 2000 to 2003, Dr.Wierenga was chief executive officer of Syrrx, Inc. Prior to joining Syrrx, from 1990 to 2000, he was senior vice president of worldwide pharmaceutical sciences, technologies and development at Parke-Davis, a division of Warner Lambert Co. Pfizer Inc acquired Warner Lambert in 2000. Prior to Parke-Davis, Dr. Wierenga worked at Upjohn Co., later Pharmacia & Upjohn, Inc., for 16 years in various positions, most recently as executive director of discovery research. Pfizer acquired Pharmacia & Upjohn, then named Pharmacia Corp., in 2002. Dr.Wierenga received a B.S. from Hope College and a Ph.D. in chemistry from Stanford University. Dr.Wierenga is a member of the boards of directors of Onyx Pharmaceuticals, Inc. and Cytokinetics, Inc.
